| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G
| EVENTIDE ASSET MANAGEMENT, LLC reports a 11.1% stake in Zentalis Pharmaceuticals, Inc. |
| 10/06/2023 |
4
| Brownstein Carrie (Chief Medical Officer) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 8,906 shares
@ $19.4265, valued at
$173k
Sold 1,722 shares
@ $19.9102, valued at
$34.3k
|
|
| 10/06/2023 |
4
| Bunker Kevin D. (Chief Scientific Officer) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 5,085 shares
@ $19.4265, valued at
$98.8k
Sold 983 shares
@ $19.9102, valued at
$19.6k
|
|
| 10/06/2023 |
4
| Epperly Melissa B, (CFO) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 4,594 shares
@ $19.4265, valued at
$89.2k
Sold 888 shares
@ $19.9102, valued at
$17.7k
|
|
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
8-K
| Investor presentation |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/16/2023 |
4
| Johnson David Michael (Director) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 19,059 shares
@ $0 |
|
| 06/16/2023 |
4
| Kariuki Enoch (Director) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 16,364 shares
@ $0 |
|
| 06/16/2023 |
4
| Skvarka Jan (Director) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 16,364 shares
@ $0 |
|
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
4
| Gallagher Cam (President) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 9,242 shares
@ $26.3989, valued at
$244k
Sold 18,526 shares
@ $26.2079, valued at
$485.5k
|
|
| 05/31/2023 |
4
| Bunker Kevin D. (Chief Scientific Officer) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 80,000 shares
@ $30.0156, valued at
$2.4M
|
|
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/26/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
4
| HAUSMAN DIANA (Director) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 39,732 shares
@ $0 |
|
| 05/10/2023 |
3
| HAUSMAN DIANA (Director) has filed a Form 3 on Zentalis Pharmaceuticals, Inc. |
| 05/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 03/02/2023 |
4
| Roth Iris (COO) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 52,500 shares
@ $0
Granted 297,500 options to buy
@ $18.87, valued at
$5.6M
|
|
|